KALA

Kala Pharmaceuticals

Last Updated:

Q3'20

Price

quotes and stock data delayed 15 minutes

Cash

$159.1

Burn Rate (Qtr)

-$27.9

Company Profile

Kala is a biopharmaceutical company focused on the discovery, development and commercialization of innovative therapies for diseases of the eye. Kala has applied its proprietary AMPPLIFY Drug Delivery Technology to a corticosteroid, loteprednol etabonate (LE), designed for ocular applications, resulting in the August 2018 FDA approval of INVELTYS® for the treatment of inflammation and pain following ocular surgery and its lead product candidate, EYSUVIS® (KPI-121 0.25%), for the temporary relief of the signs and symptoms of dry eye disease.

Drug Pipeline

Click on drug name or indication to see upcoming trial info, prior data, and more general information

Drug | Disease (links)

Stage (next event)

Catalyst Date

EYSUVIS™ (KPI-121 0.25%)

Dry Eye Disease

Quarterly Sales (Approved)

February 05, 2021 (Est)

INVELTYS™ (KPI-121 1%)

Post-operative ocular inflammation and pain

Quarterly Sales (Approved)

March 05, 2021 (Est)

Recent Posts

See what the community is saying - click to see full post

KALA - Kala Pharmaceuticals Reports Third Quarter 2020 Financial Results and Provides Corporate Update

*Disclaimer: Information provided on ampbiotechresearch.com and in any of our reports, products and services are for information only and are not investment advice. Please consult with an investment adviser and do your own diligence before making any investment decisions or taking any action.  By accessing this site, you agree to our Terms of Use and Privacy Policy that can be accessed here. Amp Core™ is a trademark of Amp Biotech Research, LLC

©2020 BY Amp Biotech Research

  • Twitter Social Icon
  • LinkedIn Social Icon